Ginkgo Bioworks Holdings (DNA) Income from Continuing Operations (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) posted Income from Continuing Operations of 76059000.0 for Q1 2026, up 5.81% on a QoQ basis from 80751000.0 in Q4 2025, and up 8.7% year-over-year from 69969140.03 in Q1 2025.
Ginkgo Bioworks Holdings (DNA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 76059000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 8.7% year-over-year to 76059000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 297865000.0 (up 35.86% YoY) and the FY2025 annual result came in at 312763000.0, up 42.83% from the prior year.
- Income from Continuing Operations was 76059000.0 for Q1 2026 at Ginkgo Bioworks Holdings, up from 80751000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 56403000.0 in Q3 2024 and bottomed at 670570000.0 in Q2 2022.
- A 5-year average of 231026176.47 and a median of 173078000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 89.22% in 2022, while the deepest fall reached 1131.22% in 2022.
- Ginkgo Bioworks Holdings' Income from Continuing Operations stood at 173078000.0 in 2022, then decreased by 22.31% to 211694000.0 in 2023, then jumped by 49.2% to 107534000.0 in 2024, then climbed by 24.91% to 80751000.0 in 2025, then increased by 5.81% to 76059000.0 in 2026.
- Business Quant data shows DNA's Income from Continuing Operations at 76059000.0 in Q1 2026, 80751000.0 in Q4 2025, and 80755000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Ginkgo Bioworks Holdings | 517.16 Mn | 373.30 Mn | 16.38 Mn | -76.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -76.06 Mn |
| Dec 31, 2025 | -80.75 Mn |
| Sep 30, 2025 | -80.76 Mn |
| Jun 30, 2025 | -60.30 Mn |
| Mar 31, 2025 | -83.31 Mn |
| Dec 31, 2024 | -107.53 Mn |
| Sep 30, 2024 | -56.40 Mn |
| Jun 30, 2024 | -217.18 Mn |
| Mar 31, 2024 | -165.91 Mn |
| Dec 31, 2023 | -211.69 Mn |
| Sep 30, 2023 | -302.89 Mn |
| Jun 30, 2023 | -173.32 Mn |
| Mar 31, 2023 | -204.97 Mn |
| Dec 31, 2022 | -173.08 Mn |
| Sep 30, 2022 | -670.13 Mn |
| Jun 30, 2022 | -670.57 Mn |
| Mar 31, 2022 | -592.59 Mn |
| Dec 31, 2021 | -1.60 Bn |
| Sep 30, 2021 | -102.41 Mn |
| Jun 30, 2021 | -54.46 Mn |